Lecture on Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Presenters:

• Dr. [Name] - Hematologist at the Walton Lasso Hall Institute of Medical Research
• Prof. Agnes - Head of the Department of Hematology, Medical University of Łódź, Poland
• Dr. Red Osakopra - Hematologist at Amsterdam University Medical Center

Key Topics Covered:

1. Presentation of MDS and AML

   • Common presentation: fatigue and cytopenia identified in routine blood tests.
   • Importance of molecular testing to distinguish between idiopathic cytopenia and clonal cytopenia.
   • Role of bone marrow examination in diagnosis.
   • History of prior cytotoxic exposure crucial for identifying therapy-related AML.

2. Diagnostic Investigations

   • Initial blood film to detect presence of blast cells.
   • Bone marrow examination consisting of aspirate and trifine.
     • Aspirate: enumerates blasts, identifies dysplasia, and presence of ringed sideroblasts.
     • Trifine: assesses fibrosis.
   • Importance of cytogenetic and molecular information for prognosis and therapy decisions.

3. Classification of Myeloid Disorders

   • Overlap between MDS and AML; classifications are imperfect.
   • WHO and ICC classifications criteria for MDS and AML.
     • Less than 5% blasts: low blast MDS.
     • 10-19% blasts: MDS/AML overlap.
     • Key genetic markers (e.g., PML-RARA, NPM1 mutation) for classifying AML.

4. Implications for Clinical Practice

   • Classification impacts treatment decisions but should be combined with clinical course, drug access, and transplant suitability.
   • MDS/AML classification allows greater flexibility in treatment choices and clinical trials.
   • Stability and trends in blast counts critical for deciding treatment aggressiveness.

5. Prognostic Models and New Classifications

   • Importance of somatic mutations in pathogenesis of MDS and AML.
   • WHO 2022 and ICC classifications include genomic features and recognize MDS/AML overlap.
   • IPSSM model incorporates molecular data improving risk stratification.

6. Advances in Risk Stratification

   • IPSSM model for personalized risk assessment and treatment planning.
   • Multiple studies show IPSSM enhances prognostic accuracy.
   • New classification criteria and subgroups influence treatment and clinical trial eligibility.

7. New Evolving Classifications

   • Introduction of the MDS/AML category blurs the distinction between MDS and AML.
   • Modern classifications incorporate genetic and molecular abnormalities for better risk assessment.
   • ELN 2022 classification highlights changes in risk categorization and treatment implications.

8. Current Challenges and Future Directions

   • Need for more effective treatments for high-risk mutations (e.g., TP53 mutations).
   • Emphasis on integrating minimal residual disease (MRD) analysis into treatment decisions.
   • Continuous updates needed in classification systems to reflect new research and treatment modalities.

Conclusion

• Classification systems are vital but only a part of comprehensive patient assessment and treatment planning.
• The continuous evolution in classification and risk models helps in tailoring better therapeutic strategies for MDS and AML patients.